Nuclear Medicine Market by Product, Application, Type, End-Users - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation

Description

List of Tables

The Global Nuclear Medicine Market is forecasted to grow significantly, with a projected USD 5,146.18 million in 2023 at a CAGR of 7.33% and expected to reach a staggering USD 8,456.64 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Nuclear Medicine Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Nuclear Medicine Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Diagnostic Products and Therapeutic Products. The Diagnostic Products is further studied across PET and SPECT. The PET is further studied across F-18 and SR-82/RB-82. The SPECT is further studied across GA-67, I-123, TC-99m, and TL-201. The Therapeutic Products is further studied across Alpha Emitters, Beta Emitters, and Brachytherapy. The Beta Emitters is further studied across I-131, Lu-117, Re-186, SM-153, and Y-90. The Brachytherapy is further studied across Cesium-131, Iodine-125, Iridium-192, and Palladium-103. The Diagnostic Products commanded largest market share of 76.04% in 2022, followed by Therapeutic Products.

Based on Application, market is studied across Bone Metastasis, Cardiology, Endocrine Tumor, Lymphoma, Oncology, and Thyroid. The Oncology commanded largest market share of 23.93% in 2022, followed by Lymphoma.

Based on Type, market is studied across Diagnostic and Therapeutic. The Diagnostic is further studied across PET Procedures and SPECT Procedures. The Therapeutic is further studied across Alpha Emitter Procedures, Beta Emitter Procedures, and Brachytherapy Procedures. The Diagnostic commanded largest market share of 77.34% in 2022, followed by Therapeutic.

Based on End-Users, market is studied across Hospitals & Diagnostic Centers and Research institutes. The Hospitals & Diagnostic Centers commanded largest market share of 91.85% in 2022, followed by Research institutes.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 39.48% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Nuclear Medicine Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Nuclear Medicine Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Nuclear Medicine Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Nuclear Medicine Market?

4. What is the competitive strategic window for opportunities in the Global Nuclear Medicine Market?

5. What are the technology trends and regulatory frameworks in the Global Nuclear Medicine Market?

6. What is the market share of the leading vendors in the Global Nuclear Medicine Market?

7. What modes and strategic moves are considered suitable for entering the Global Nuclear Medicine Market?

Product Code: MRR-A339DAEFAF60

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Nuclear Medicine Market, by Product, 2022 vs 2030
4.3. Nuclear Medicine Market, by Application, 2022 vs 2030
4.4. Nuclear Medicine Market, by Type, 2022 vs 2030
4.5. Nuclear Medicine Market, by End-Users, 2022 vs 2030
4.6. Nuclear Medicine Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising Incidence and Prevalence of Cancer Worldwide
  - 5.1.1.2. Increasing Use of PET and SPECT to Diagnose Heart disease and Neurological Disorders
  - 5.1.1.3. International Organizations' Initiatives and Awareness Supporting Nuclear Medicine
- 5.1.2. Restraints
  - 5.1.2.1. Shorter Half-Life of Nuclear Medicine
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging Popularity of Theranostics in Nuclear Medicine
  - 5.1.3.2. Continuous Product Developments and Advancements in Patented Technologies
- 5.1.4. Challenges
  - 5.1.4.1. Lack of Knowledge, Training, and Availability of Nuclear Medicine in Developing Countries
  - 5.1.4.2. Limited Availability of Skilled Radiologists and Practitioners Worldwide
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Nuclear Medicine Market, by Product

6.1. Introduction
6.2. Diagnostic Products
- 6.2.1. PET
  - 6.2.1.1. F-18
  - 6.2.1.2. SR-82/RB-82
- 6.2.2. SPECT
  - 6.2.2.1. GA-67
  - 6.2.2.2. I-123
  - 6.2.2.3. TC-99m
  - 6.2.2.4. TL-201
6.3. Therapeutic Products
- 6.3.1. Alpha Emitters
- 6.3.2. Beta Emitters
  - 6.3.2.1. I-131
  - 6.3.2.2. Lu-117
  - 6.3.2.3. Re-186
  - 6.3.2.4. SM-153
  - 6.3.2.5. Y-90
- 6.3.3. Brachytherapy
  - 6.3.3.1. Cesium-131
  - 6.3.3.2. Iodine-125
  - 6.3.3.3. Iridium-192
  - 6.3.3.4. Palladium-103

7. Nuclear Medicine Market, by Application

7.1. Introduction
7.2. Bone Metastasis
7.3. Cardiology
7.4. Endocrine Tumor
7.5. Lymphoma
7.6. Oncology
7.7. Thyroid

8. Nuclear Medicine Market, by Type

8.1. Introduction
8.2. Diagnostic
- 8.2.1. PET Procedures
- 8.2.2. SPECT Procedures
8.3. Therapeutic
- 8.3.1. Alpha Emitter Procedures
- 8.3.2. Beta Emitter Procedures
- 8.3.3. Brachytherapy Procedures

9. Nuclear Medicine Market, by End-Users

9.1. Introduction
9.2. Hospitals & Diagnostic Centers
9.3. Research institutes

10. Americas Nuclear Medicine Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Nuclear Medicine Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Nuclear Medicine Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing